A selective SGLT2 inhibitor (IC50 = 3.1 nM) that has been shown in clinical trials of patients with type 2 diabetes to lower fasting and postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting substrate utilization from glucose to lipids